Perrigo OTC Growth Rides Innovation Path Wider Than Switches
Executive Summary
When Perrigo executives confirmed their faith during an earnings briefing in the firm's OTC private label as its primary revenue driver, some analysts wanted more as assurance that the business will continue stabilizing the firm.
You may also be interested in...
Perrigo Predicts Upturn On OTC Private Label Breadth, Depth And Bandwidth
Perrigo counts on its OTC private label dominance to thwart new store brand entries and give it a leg-up in e-commerce sales, which are growing at 50% year-to-year. Private label is "a distinctly different business than the national brand space," says consumer health executive Jeffrey Needham.
Perrigo Predicts Upturn On OTC Private Label Breadth, Depth And Bandwidth
Perrigo counts on its OTC private label dominance to thwart new store brand entries and give it a leg-up in e-commerce sales, which are growing at 50% year-to-year. Private label is "a distinctly different business than the national brand space," says consumer health executive Jeffrey Needham.
FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap
CDER has been studying ideas such as pictograms to communicate instructions on administering opioid-reversal medication, but officials can’t predict when new approaches might help enable FDA to propose regulatory changes in the US switch process.